E-Book, Englisch, 872 Seiten
Shoenfeld / Gershwin / Gershwin MD Autoantibodies
2. Auflage 2011
ISBN: 978-0-08-046723-8
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark
E-Book, Englisch, 872 Seiten
ISBN: 978-0-08-046723-8
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark
Autoantibodies was published and presented in November 2006 at the International Congress of Autoimmunity in Sorrento, a small town in Campania, Italy. The Congress also celebrated the 100th anniversary of the first routine test for autoantibodies. An autoantibody is a type of antibody that is produced by the immune system and that fights one or more of a person's own proteins. These autoantibodies cause autoimmune diseases such as lupus erythematosus.
The authors and editors of this book provide a critical review of autoantibodies and their primary functions. They cite a number of major developments in the field of autoantibodies, including the detection of autoantibodies in which a healthy person is a carrier; the discovery that autoantibodies can be both pathogenic and protective in some cases; and the development of a device that will help monitor and detect a specific autoantibody using a small amount of serum and proteomic arrays. Aside from the pathogenic and protective autoantibodies, the book also discusses irrelevant autoantibodies, as these may be relevant for future research. It also addresses the importance of the autoantibodies in a person's body.
Clinical physicians, as well as scientists interested in the significance of autoantibodies in the human body, will find this book relevant. It will also be of interest to those who suffer from an autoimmune disease.
* Incudes and exhaustive list of autoantibodies not covered by other publications
* Short reviews can easily be checked for quick reference information
* Both basic and clinical aspects are covered
Autoren/Hrsg.
Weitere Infos & Material
1;Title Page;4
2;Copyright Page;5
3;Table of Contents;8
4;Foreword;16
5;Preface;20
6;About the Editors;22
7;List of Contributors;24
8;Introduction;34
9;Part I Introduction: Autoantibodies-Unique Characteristics;36
9.1;Chapter 1 What is an Autoantibody?;38
9.1.1;Abstract;38
9.1.2;Introduction;38
9.1.3;Characterization of autoimmune diseases;39
9.1.4;Tolerance;39
9.1.5;Concluding remarks;40
9.1.6;References;40
9.2;Chapter 2 Natural Autoantibodies, Heralding, Protecting and Inducing Autoimmunity;42
9.2.1;Abstract;42
9.2.2;Historical notes;42
9.2.3;The origin of NAbs;43
9.2.4;NAbs and autoimmunity;44
9.2.5;NAbs and the innate immune system;44
9.2.6;Apoptosis and NAbs;45
9.2.7;Protective NAbs;45
9.2.8;References;47
9.3;Chapter 3 Molecular Mimicry;48
9.3.1;Abstract;48
9.3.2;Historical notes;48
9.3.3;Forms of molecular mimicry;49
9.3.4;Natural autoantibodies and molecular mimicry;51
9.3.5;Animal model of molecular mimicry;52
9.3.6;Clinical utility;52
9.3.7;Conclusion;53
9.3.8;References;54
9.4;Chapter 4 Affinity and Avidity of Autoantibodies;56
9.4.1;Abstract;56
9.4.2;Historical notes;56
9.4.3;Avidity and affinity;57
9.4.4;Clinical utility in autoimmune disorders;61
9.4.5;Take-home messages;62
9.4.6;References;63
9.5;Chapter 5 Pathogenic Mechanisms and Clinical Relevance of Autoantibodies;64
9.5.1;Abstract;64
9.5.2;Introduction;64
9.5.3;Cell surface binding and lysis (cytotoxicity);65
9.5.4;Binding to cell surface receptors without cytolysis;66
9.5.5;Immune complex–mediated damage;67
9.5.6;Translocation of intracellular antigens to cell membrane;68
9.5.7;Penetration into living cells;69
9.5.8;Binding to extracellular molecules;69
9.5.9;Take-home messages;70
9.5.10;References;70
9.6;Chapter 6 Native Autoantigens Versus Recombinant Autoantigens;72
9.6.1;Abstract;72
9.6.2;Introduction;72
9.6.3;Detection of autoantibodies;73
9.6.4;ELISA;73
9.6.5;Native autoantigens;75
9.6.6;Recombinant autoantigens;76
9.6.7;Criteria for usage of autoantigens in immunoassays;78
9.6.8;Limitations of recombinant technology for the production of autoantigens;79
9.6.9;Acknowledgements;79
9.6.10;Take-home messages;79
9.6.11;References;79
9.7;Chapter 7 Redox-Reactive Autoantibodies;82
9.7.1;Abstract;82
9.7.2;Historical notes;83
9.7.3;Autoantigens;83
9.7.4;Autoantibodies;84
9.7.5;Acknowledgements;87
9.7.6;Take-home messages;87
9.7.7;References;87
9.8;Chapter 8 Predictive Autoantibodies;90
9.8.1;Abstract;90
9.8.2;Introduction;90
9.8.3;Prediction of disease;91
9.8.4;Prediction of specific clinical manifestations;91
9.8.5;Hierarchy of autoantibodies;92
9.8.6;Combining HLA and predictive antibodies in prediction;93
9.8.7;Combining specific genes and antibody testing;93
9.8.8;Implications and future directions;93
9.8.9;Take-home messages;95
9.8.10;References;95
9.9;Chapter 9 Autoantibody Subclasses;96
9.9.1;Abstract;96
9.9.2;Historical notes;96
9.9.3;The findings;97
9.9.4;The methods;100
9.9.5;The causes;100
9.9.6;The consequences;101
9.9.7;Conclusion;101
9.9.8;References;102
9.10;Chapter 10 Idiotypes and Anti-Idiotypes;104
9.10.1;Abstract;104
9.10.2;Historical notes;105
9.10.3;The autoantigen(s);105
9.10.4;Structure of idiotypes;106
9.10.5;Genetics;106
9.10.6;Autoantibodies;106
9.10.7;Physiologic role;107
9.10.8;Pathogenic role;107
9.10.9;Clinical utility;109
9.10.10;Summary;110
9.10.11;Take-home messages;110
9.10.12;References;111
9.11;Chapter 11 Novel Diagnostic Methods for Autoantibody Detection;112
9.11.1;Abstract;112
9.11.2;The use of single autoantibody tests in the diagnosis and classification of autoimmune diseases: The ‘old’ technologies;113
9.11.3;Multiplex technologies for the study of autoantibody profiles: The ‘new’ technologies;113
9.11.4;The predictive role of autoantibody profiles;116
9.11.5;Take-home messages;116
9.11.6;References;117
10;Part II Allergic Disease Autoantibodies;118
10.1;Chapter 12 Human IgE–Specific Autoantibodies and Autoantibodies to IgE Receptors;120
10.1.1;Summary;120
10.1.2;Human IgE;121
10.1.3;IgE receptors;124
10.1.4;Antibodies to IgE receptors;125
10.1.5;Take-home messages;126
10.1.6;References;126
11;Part III Antineutrophil Antibodies;128
11.1;Chapter 13 Antineutrophil Cytoplasmic Autoantibodies with Specificity for Myeloperoxidase;130
11.1.1;Abstract;130
11.1.2;Historical notes;131
11.1.3;The autoantigen;131
11.1.4;The autoantibodies;133
11.1.5;Clinical utility;135
11.1.6;Take-home messages;137
11.1.7;References;137
11.2;Chapter 14 Antineutrophil Cytoplasmic Autoantibodies with Specificity for Proteinase 3;140
11.2.1;Abstract;140
11.2.2;Historical notes;141
11.2.3;Autoantigen;141
11.2.4;Autoantibody;142
11.2.5;Clinical utility;143
11.2.6;Take-home messages;144
11.2.7;References;144
11.3;Chapter 15 Neutrophil-Specific Antinuclear and Anti-cytoplasmic Antibodies in Chronic Inflammatory Diseases;146
11.3.1;Abstract;146
11.3.2;Historical notes;147
11.3.3;Autoantigens;147
11.3.4;Autoantibody;148
11.3.5;Clinical utility and prognostic value;149
11.3.6;Conclusions;151
11.3.7;References;151
11.4;Chapter 16 Antineutrophil Cytoplasmatic Autoantibodies with Specificity to Proteinase 3;154
11.4.1;Abstract;154
11.4.2;Historical notes;155
11.4.3;Autoantigens;155
11.4.4;The autoantibodies;156
11.4.5;Clinical utility;159
11.4.6;Take-home messages;161
11.4.7;References;161
12;Part IV Introduction: Antinuclear Antibodies;162
12.1;Chapter 17 Antinuclear Antibodies: General Introduction;164
12.1.1;Abstract;164
12.1.2;Historical notes;164
12.1.3;Autoantigens;165
12.1.4;Autoantibodies;165
12.1.5;Take-home messages;167
12.1.6;References;168
12.2;Chapter 18 Antinucleolar Antibodies;170
12.2.1;Abstract;170
12.2.2;Historical notes;170
12.2.3;Autoantigen;171
12.2.4;Autoantibodies;171
12.2.5;Conclusion;173
12.2.6;Take-home messages;174
12.2.7;References;174
12.3;Chapter 19 Anti-Chromatin (Nucleosome) Autoantibodies;176
12.3.1;Abstract;176
12.3.2;Historical notes;177
12.3.3;Autoantigen;177
12.3.4;Autoantibody;178
12.3.5;Clinical utility;180
12.3.6;Conclusion;183
12.3.7;Take-home messages;183
12.3.8;References;183
12.4;Chapter 20 Centromere Autoantibodies;186
12.4.1;Abstract;186
12.4.2;Historical notes;186
12.4.3;Autoantigen;187
12.4.4;Autoantibody;189
12.4.5;Methods of detection;190
12.4.6;Clinical utility;190
12.4.7;Take-home messages;192
12.4.8;References;192
12.5;Chapter 21 dsDNA Autoantibodies;194
12.5.1;Abstract;194
12.5.2;Historical notes;195
12.5.3;Autoantigen;195
12.5.4;Autoantibody;196
12.5.5;Clinical utility;199
12.5.6;References;202
12.6;Chapter 22 Histone Autoantibodies;204
12.6.1;Abstract;204
12.6.2;Historical notes;204
12.6.3;The autoantigens;205
12.6.4;Autoantibodies;208
12.6.5;Clinical utility;210
12.6.6;Take-home messages;211
12.6.7;References;211
12.7;Chapter 23 Ku and Ki Autoantibodies;212
12.7.1;Summary;212
12.7.2;Historical notes;212
12.7.3;Autoantigens;213
12.7.4;Autoantibodies;215
12.7.5;Clinical utility;216
12.7.6;Take-home messages;219
12.7.7;References;219
12.8;Chapter 24 Neuronal Nuclear Autoantibodies, Type 1 (Hu);220
12.8.1;Abstract;220
12.8.2;Historical notes;221
12.8.3;Autoantigens;221
12.8.4;Autoantibody;222
12.8.5;Clinical utility;223
12.8.6;Take-home messages;225
12.8.7;References;225
12.9;Chapter 25 Nuclear Envelope Protein Autoantibodies/Antilamin Autoantibodies;226
12.9.1;Summary;226
12.9.2;Historical notes;227
12.9.3;Autoantigens;227
12.9.4;Autoantibody;229
12.9.5;Take-home messages;230
12.9.6;References;230
12.10;Chapter 26 Anti-Nucleosome Autoantibodies;232
12.10.1;Abstract;232
12.10.2;Historical notes;233
12.10.3;Autoantigen;233
12.10.4;Autoantibody;234
12.10.5;Clinical utility;236
12.10.6;Take-home messages;238
12.10.7;References;238
12.11;Chapter 27 Proliferating Cell Nuclear Antigen Autoantibodies;240
12.11.1;Historical notes;240
12.11.2;Autoantigens;241
12.11.3;Autoantibodies;242
12.11.4;Clinical utility;243
12.11.5;Conclusion;245
12.11.6;Acknowledgements;245
12.11.7;References;245
12.12;Chapter 28 Anti-RA33 Antibodies (Antibodies to the Heterogeneous Nuclear Ribonucleoprotein A2);246
12.12.1;Abstract;246
12.12.2;Historical notes;247
12.12.3;Autoantigen;247
12.12.4;Autoantibody;248
12.12.5;Clinical utility;249
12.12.6;Take-home messages;250
12.12.7;References;250
12.13;Chapter 29 Anti-Ribosomal P Antibodies;252
12.13.1;Abstract;252
12.13.2;Autoantigen;252
12.13.3;Autoantibody;253
12.13.4;Assays for anti-rib-P Ab detection;254
12.13.5;Serological test performance;256
12.13.6;Clinical studies;256
12.13.7;Conclusion;257
12.13.8;Take-home messages;257
12.13.9;References;257
12.14;Chapter 30 SS-A (Ro) Autoantibodies;260
12.14.1;Historical notes;260
12.14.2;Autoantigen;260
12.14.3;Autoantibodies;262
12.14.4;Clinical utility;264
12.14.5;Conclusion;264
12.14.6;References;265
12.15;Chapter 31 Topoisomerase-I (Scl-70) Autoantibodies;266
12.15.1;Abstract;266
12.15.2;Historical notes;267
12.15.3;Autoantigen;267
12.15.4;Autoantibody;268
12.15.5;Clinical utility;271
12.15.6;Take-home messages;272
12.15.7;References;272
12.16;Chapter 32 SS-B (La) Autoantibodies;274
12.16.1;Abstract;274
12.16.2;Historical notes;274
12.16.3;Autoantigen;275
12.16.4;Autoantibody;277
12.16.5;Clinical utility;279
12.16.6;Take-home messages;280
12.16.7;References;281
12.17;Chapter 33 Anti-RNA Polymerase III Antibodies;282
12.17.1;Abstract;282
12.17.2;Historical notes;283
12.17.3;Autoantigen(s);283
12.17.4;Autoantibody;285
12.17.5;Clinical utility;287
12.17.6;Take-home messages;289
12.17.7;References;289
13;Part V Autoantibodies to Biologic Factors/Structures;290
13.1;Chapter 34 GW Bodies, P Bodies and Components of the miRNA Pathway;292
13.1.1;Abstract;292
13.1.2;Historical notes;292
13.1.3;Autoantigen;293
13.1.4;Autoantibody;295
13.1.5;Clinical utility;295
13.1.6;Take-home messages;296
13.1.7;References;297
13.2;Chapter 35 Golgi Complex and Endosome Antibodies;298
13.2.1;Abstract;298
13.2.2;Autoantigen;298
13.2.3;Autoantibody;301
13.2.4;Clinical utility;303
13.2.5;Take-home messages;305
13.2.6;References;305
13.3;Chapter 36 p53 Autoantibodies;306
13.3.1;Abstract;306
13.3.2;Historical notes;306
13.3.3;Autoantigen;307
13.3.4;Autoantibody;309
13.3.5;Clinical utility;310
13.3.6;Take-home messages;311
13.3.7;References;311
13.4;Chapter 37 Human Antiganglioside Autoantibodies;312
13.4.1;Abstract;312
13.4.2;Historical notes;313
13.4.3;Autoantigens;313
13.4.4;Autoantibody;314
13.4.5;Clinical utility;316
13.4.6;Take-home messages;318
13.4.7;Acknowledgement;318
13.4.8;References;318
13.5;Chapter 38 Human Anti-alpha-Galactosyl Antibodies;320
13.5.1;Abstract;320
13.5.2;Historical notes;321
13.5.3;Autoantigen;321
13.5.4;Autoantibody;322
13.5.5;Clinical utility;323
13.5.6;Take-home messages;325
13.5.7;References;325
13.6;Chapter 39 Autoantibodies in Therapeutic Preparations of Human Intravenous Immunoglobulin (IVIG);328
13.6.1;Abstract;328
13.6.2;Historical notes;329
13.6.3;Autoantigens;329
13.6.4;Autoantibodies;329
13.6.5;Clinical utility;331
13.6.6;Take-home messages;332
13.6.7;References;332
13.7;Chapter 40 Cytokine Antibodies;334
13.7.1;Abstract;334
13.7.2;Historical notes;335
13.7.3;The autoantigens;336
13.7.4;The autoantibodies;338
13.7.5;Clinical utility;340
13.7.6;Take-home messages;342
13.7.7;Acknowledgement;342
13.7.8;References;342
13.8;Chapter 41 Cytoskeletal Autoantibodies/Anti-Actin Antibodies;344
13.8.1;Abstract;344
13.8.2;Historical notes;344
13.8.3;The autoantigen;345
13.8.4;Autoantibody;346
13.8.5;Clinical utility;350
13.8.6;Take-home messages;350
13.8.7;References;351
13.9;Chapter 42 Fibrillarin Autoantibodies;352
13.9.1;Abstract;352
13.9.2;Historical notes;352
13.9.3;Autoantigen;353
13.9.4;Autoantibody;354
13.9.5;Clinical utility;356
13.9.6;Take-home messages;358
13.9.7;Acknowledgements;358
13.9.8;References;358
13.10;Chapter 43 Fibronectin Autoantibodies;360
13.10.1;Abstract;360
13.10.2;Historical notes;360
13.10.3;Autoantigen;361
13.10.4;Autoantibody;362
13.10.5;Clinical utility;363
13.10.6;Take-home messages;364
13.10.7;References;364
13.11;Chapter 44 Interferon-Inducible Protein IFI16 Autoantibodies;366
13.11.1;Abstract;366
13.11.2;Historical notes;366
13.11.3;Autoantigen;367
13.11.4;Autoantibodies;369
13.11.5;Clinical utility;370
13.11.6;Take-home messages;371
13.11.7;References;371
14;Part VI Cardiac Autoantibodies;374
14.1;Chapter 45 Autoantibodies in Atherosclerosis;376
14.1.1;Abstract;376
14.1.2;Introduction;377
14.1.3;Oxidized LDL and antibodies to oxidized LDL;377
14.1.4;Phosphorylcholine and anti-phosphorylcholine antibodies;379
14.1.5;Phospholipids and antiphospholipid antibodies;380
14.1.6;Take-home messages;381
14.1.7;References;381
14.2;Chapter 46 Heat Shock Protein Autoantibodies;384
14.2.1;Abstract;384
14.2.2;Historical notes and the autoimmune hypothesis of atherogenesis;384
14.2.3;Autoantigen;385
14.2.4;Take-home messages;388
14.2.5;References;388
14.3;Chapter 47 Myocardial Autoantibodies and their Clinical Significance;390
14.3.1;Abstract;390
14.3.2;Historical and general perspective;391
14.3.3;Infectious agents implicated in human DCM;393
14.3.4;Autoantigens identified in sera of IDCM patients;395
14.3.5;Immunogobulin apheresis as a therapeutic option in DCM;397
14.3.6;Clinical relevance of cardiac specific autoantibodies in human DCM;397
14.3.7;Take-home messages;399
14.3.8;References;399
15;Part VII Endocrine Autoantibodies;402
15.1;Chapter 48 Glutamic Acid Decarboxylase Autoantibodies;404
15.1.1;Abstract;404
15.1.2;Historical notes;405
15.1.3;Autoantigen;405
15.1.4;Autoantibody;407
15.1.5;Clinical utility;409
15.1.6;Take-home messages;413
15.1.7;References;413
15.2;Chapter 49 Humoral Immunity in Type 1 Diabetes Mellitus;414
15.2.1;Abstract;414
15.2.2;Historical notes;415
15.2.3;Autoantigen;415
15.2.4;Autoantibody;418
15.2.5;Clinical utility;421
15.2.6;Take-home messages;422
15.2.7;References;422
15.3;Chapter 50 Antibodies to Adrenal, Gonadal Tissues and Steroidogenic Enzymes;424
15.3.1;Abstract;424
15.3.2;Historical notes;425
15.3.3;Adrenal and gonadal autoantigens;425
15.3.4;Autoantibodies to adrenal cortex and to 21-OH;428
15.3.5;Autoantibodies to gonadal tissue and steroidogenic enzymes (17alpha-OHAbs and P450sccAbs);432
15.3.6;Take-home messages;434
15.3.7;Acknowledgements;435
15.3.8;References;435
15.4;Chapter 51 Thyroglobulin, Thyroperoxidase, and Thyrotropin-Receptor Autoantibodies;438
15.4.1;Historical notes;438
15.4.2;Thyroglobulin antibodies;439
15.4.3;Thyroperoxidase antibodies;442
15.4.4;Clinical utility;443
15.4.5;Thyrotropin-receptor antibodies;445
15.4.6;Take-home messages;448
15.4.7;References;448
16;Part VIII GI and Liver Autoantibodies;450
16.1;Chapter 52 Anti-Intestinal Goblet Cell Antibodies;452
16.1.1;Summary;452
16.1.2;Historical notes;452
16.1.3;Autoantigen;454
16.1.4;Autoantibody;454
16.1.5;Clinical utility;455
16.1.6;Take-home messages;457
16.1.7;References;457
16.2;Chapter 53 Tumor-Associated Autoantibodies;458
16.2.1;Summary;458
16.2.2;Historical notes;459
16.2.3;Autoantigenic targets of tumor-associated AAB;459
16.2.4;Relevance of tumor-associated AAB;466
16.2.5;Tumor-associated AAB – Biomarkers for the prediction and early diagnosis of cancer?;467
16.2.6;Take-home messages;469
16.2.7;References;469
16.3;Chapter 54 Cryoglobulins and Cryoglobulins Secondary to Hepatitis C Virus Infection;472
16.3.1;Abstract;472
16.3.2;Historical notes;472
16.3.3;Cryoprecipitation;473
16.3.4;Autoantigen;473
16.3.5;Autoantibody;474
16.3.6;Methods of detection;475
16.3.7;Prevalence/prognosis;475
16.3.8;Treatment;475
16.3.9;Take-home messages;476
16.3.10;References;476
16.4;Chapter 55 Anti-Tissue Transglutaminase and Anti-Endomyisial Antibodies;478
16.4.1;Abstract;478
16.4.2;Historical notes;479
16.4.3;Autoantigen;479
16.4.4;Autoantibody;480
16.4.5;Clinical utility;482
16.4.6;Take-home messages;485
16.4.7;References;485
16.5;Chapter 56 Anti-Gliadin Antibodies;486
16.5.1;Abstract;486
16.5.2;Historical notes;486
16.5.3;The antigen;487
16.5.4;The antibody;488
16.5.5;Clinical utility;489
16.5.6;Take-home messages;491
16.5.7;References;491
16.6;Chapter 57 Reticulin Autoantibodies;492
16.6.1;Abstract;492
16.6.2;Historical notes;492
16.6.3;Autoantigen;493
16.6.4;Autoantibody;494
16.6.5;Clinical utility;496
16.6.6;Take-home messages;496
16.6.7;References;497
16.7;Chapter 58 Liver Cytosol Antigen Type 1 Autoantibodies, Liver Kidney Microsomal Autoantibodies, and Liver Microsomal Autoantibodies;498
16.7.1;Abstract;498
16.7.2;Liver kidney microsomal autoantibodies and liver microsomal autoantibodies;499
16.7.3;Autoantigen and autoantibody definitions of LKM/LM autoantibodies;499
16.7.4;Hepatitis D-associated microsomal autoantibodies;503
16.7.5;Microsomal autoantibodies in autoimmune hepatitis associated with the autoimmune polyglandular syndrome;503
16.7.6;Microsomal autoantibodies and drug reactions;504
16.7.7;Microsomal autoantibodies of unknown relevance;504
16.7.8;General role of anti-microsomal autoantibodies;504
16.7.9;Liver cytosolic autoantibodies;505
16.7.10;Autoantibody definition and autoantigen;505
16.7.11;Clinical utility;505
16.7.12;Take-home messages;505
16.7.13;References;506
16.8;Chapter 59 Antimitochondrial Antibodies;508
16.8.1;Summary;508
16.8.2;Historical notes;508
16.8.3;Autoantigens;509
16.8.4;Autoantibody;509
16.8.5;Clinical utility;510
16.8.6;Take-home messages;511
16.8.7;References;511
16.9;Chapter 60 Parietal Cell and Intrinsic Factor Autoantibodies;514
16.9.1;Summary;514
16.9.2;Historical notes;515
16.9.3;Gastric parietal cell autoantigen;515
16.9.4;Gastric parietal cell autoantibody;516
16.9.5;Intrinsic factor autoantigen;516
16.9.6;Intrinsic factor autoantibody;517
16.9.7;Clinical utility;517
16.9.8;Parietal cell antibody;517
16.9.9;Intrinsic factor antibody;518
16.9.10;Take-home messages;520
16.9.11;References;521
16.10;Chapter 61 Smooth Muscle Antibodies;522
16.10.1;Abstract;522
16.10.2;Historical notes;522
16.10.3;Autoantigen;523
16.10.4;Autoantibody;523
16.10.5;Clinical utility;524
16.10.6;References;525
17;Part IX Hematologic Autoantibodies;528
17.1;Chapter 62 Coagulation Factor Autoantibodies;530
17.1.1;Abstract;530
17.1.2;Coagulation pathways;530
17.1.3;Historical notes: Autoantibodies to coagulation factor VIII (FVIII);531
17.1.4;Autoantigen;531
17.1.5;Autoantibody;533
17.1.6;Clinical utility;535
17.1.7;Autoantibodies to other coagulation factors;537
17.1.8;Autoantibodies to von Willebrand factor autoantigen;537
17.1.9;Take-home messages;545
17.1.10;References;545
17.2;Chapter 63 Autoantibodies in Heparin-Induced Thrombocytopenia;546
17.2.1;Abstract;546
17.2.2;Historical notes;547
17.2.3;Autoantigen: The heparin–platelet factor 4 complex;547
17.2.4;Autoantibody;549
17.2.5;Clinical utility;551
17.2.6;Take-home messages;553
17.2.7;References;553
17.3;Chapter 64 Platelet Autoantibodies;556
17.3.1;Abstract;556
17.3.2;Historical notes;557
17.3.3;Platelet autoantigens;557
17.3.4;ITP;557
17.3.5;Platelet autoantibodies;559
17.3.6;Clinical utility;560
17.3.7;Take-home messages;561
17.3.8;References;561
17.4;Chapter 65 Red Cell Autoantibodies;564
17.4.1;Abstract;564
17.4.2;Introduction;565
17.4.3;Autoantigen;565
17.4.4;Clinical utility;568
17.4.5;Take-home messages;569
17.4.6;Acknowledgment;570
17.4.7;References;570
17.5;Chapter 66 Lymphocytotoxic Autoantibodies;572
17.5.1;Abstract;572
17.5.2;Historical notes;573
17.5.3;The autoantigen;573
17.5.4;The autoantibodies;575
17.5.5;Clinical utility;577
17.5.6;Clinical parameters;577
17.5.7;Take-home messages;578
17.5.8;References;578
18;Part X Kidney Autoantibodies;580
18.1;Chapter 67 Anti-ATP Synthase Beta-Chain Autoantibodies;582
18.1.1;Abstract;582
18.1.2;Historical notes;582
18.1.3;Autoantigen;583
18.1.4;Autoantibody;583
18.1.5;Clinical utility;585
18.1.6;Take-home messages;587
18.1.7;References;587
18.2;Chapter 68 Glomerular Basement Membrane Autoantibodies;588
18.2.1;Abstract;588
18.2.2;Historical notes;588
18.2.3;Autoantigen;589
18.2.4;Autoantibody;590
18.2.5;Clinical utility;592
18.2.6;Take-home messages;593
18.2.7;References;594
18.3;Chapter 69 Nephritic Factor Autoantibodies;596
18.3.1;Historical notes;596
18.3.2;The autoantigen;597
18.3.3;Autoantibodies;597
18.3.4;Clinical utility;599
18.3.5;Take-home messages;600
18.3.6;References;600
19;Part XI Neurological System Autoantibodies;602
19.1;Chapter 70 Acetylcholine Receptor and Muscle Specific Kinase Autoantibodies;604
19.1.1;Abstract;604
19.1.2;Historical notes;604
19.1.3;The autoantigen;605
19.1.4;The autoantibody;606
19.1.5;Clinical utility;608
19.1.6;Muscle specific kinase;610
19.1.7;Conclusion;610
19.1.8;References;611
19.2;Chapter 71 Myositis Autoantibodies: Aminoacyl-tRNA Synthetase, Signal Recognition Particle, Mi-2, and PM-Scl Autoantibodies;612
19.2.1;Abstract;612
19.2.2;Historical notes;613
19.2.3;Autoantigen;616
19.2.4;Autoantibodies;619
19.2.5;Clinical utility;621
19.2.6;Take-home messages;623
19.2.7;References;623
19.3;Chapter 72 Anti-MOG Antibodies;626
19.3.1;Abstract;626
19.3.2;Historical notes;627
19.3.3;Autoantigen;627
19.3.4;Autoantibody;629
19.3.5;Clinical utility;632
19.3.6;Prognostic value;632
19.3.7;Take-home messages;633
19.3.8;References;633
19.4;Chapter 73 Antibodies to Hsp 70 in Inner Ear Disease;634
19.4.1;Abstract;634
19.4.2;Historical notes;634
19.4.3;Autoantigen;635
19.4.4;Autoantibody;636
19.4.5;Clinical utility;637
19.4.6;Take-home messages;639
19.4.7;References;639
19.5;Chapter 74 Autoantibodies in the Lambert–Eaton Myasthenic Syndrome (LEMS) and Amyotrophic Lateral Sclerosis (ALS);640
19.5.1;Abstract;640
19.5.2;Historical notes;641
19.5.3;The Lambert–Eaton myasthenic syndrome;641
19.5.4;Amyotrophic lateral sclerosis;641
19.5.5;Autoantigen: Voltage-gated calcium channels;642
19.5.6;Autoantibody;642
19.5.7;Clinical utility;643
19.5.8;Take-home messages;645
19.5.9;References;645
19.6;Chapter 75 Ganglioside Autoantibodies;646
19.6.1;Abstract;646
19.6.2;Historical notes;646
19.6.3;The autoantigen(s);647
19.6.4;Autoantibodies;648
19.6.5;Clinical utility;651
19.6.6;Take-home messages;652
19.6.7;References;653
19.7;Chapter 76 Myelin Associated Antibodies: Myelin-Associated Glycoprotein Autoantibodies, Myelin Basic Protein Autoantibodies and Myelin...;654
19.7.1;Abstract;654
19.7.2;Myelin-associated glycoprotein;655
19.7.3;Myelin basic protein and proteolipid protein;656
19.7.4;Conclusions;659
19.7.5;References;660
19.8;Chapter 77 Paraneoplastic Neurological Antibodies: Nuclear;662
19.8.1;Abstract;662
19.8.2;Historical notes;663
19.8.3;Autoantigens;663
19.8.4;Autoantibodies;664
19.8.5;Clinical utility;668
19.8.6;Take-home messages;669
19.8.7;References;670
19.9;Chapter 78 Paraneoplastic Neurological Antibodies: Purkinje Cell Cytoplasm;672
19.9.1;Abstract;672
19.9.2;Historical notes;673
19.9.3;Autoantigens;673
19.9.4;Autoantibodies;674
19.9.5;Clinical utility;676
19.9.6;Take-home messages;677
19.9.7;References;677
19.10;Chapter 79 Paraneoplastic Neurological Antibodies: Additional Reactivities;680
19.10.1;Abstract;680
19.10.2;Historical notes;681
19.10.3;Autoantigens;681
19.10.4;Autoantibodies;682
19.10.5;Clinical utility;685
19.10.6;Take-home messages;687
19.10.7;References;687
19.11;Chapter 80 Retinal Autoantibodies;688
19.11.1;Abstract;688
19.11.2;Historical notes;689
19.11.3;Autoantigen;689
19.11.4;Autoantibody;690
19.11.5;Clinical utility;692
19.11.6;Take-home messages;692
19.11.7;References;693
19.12;Chapter 81 Autoantibodies in Epilepsy;694
19.12.1;Abstract;694
19.12.2;Historical background;694
19.12.3;Voltage-gated potassium channel antibodies;695
19.12.4;Glutamic acid decarboxylase antibodies;696
19.12.5;Other autoantibodies in epilepsy;698
19.12.6;Conclusions;699
19.12.7;Take-home messages;699
19.12.8;References;699
20;Part XII Rheumatic Disease Autoantibodies;702
20.1;Chapter 82 Anti-Fodrin Antibodies;704
20.1.1;Abstract;704
20.1.2;Autoantigen;704
20.1.3;Autoantibody;705
20.1.4;Clinical utility;706
20.1.5;Take-home messages;709
20.1.6;References;709
20.2;Chapter 83 Antibodies to Laminin;710
20.2.1;Abstract;710
20.2.2;Historical notes;710
20.2.3;Autoantigen;711
20.2.4;Autoantibody;712
20.2.5;Clinical utility;713
20.2.6;Take-home messages;714
20.2.7;References;715
20.3;Chapter 84 Autoantibodies Against Muscarinic Acetylcholine Receptor in Patients with Sjögren’s Syndrome;716
20.3.1;Abstract;716
20.3.2;Historical notes;717
20.3.3;Autoantigen;717
20.3.4;Autoantibody;717
20.3.5;Clinical utility;718
20.3.6;Take-home messages;719
20.3.7;References;719
20.4;Chapter 85 Beta2-Glycoprotein I Autoantibodies;722
20.4.1;Abstract;722
20.4.2;Historical notes;723
20.4.3;The Autoantigen;723
20.4.4;The autoantibodies;724
20.4.5;Clinical utility;726
20.4.6;Take-home messages;727
20.4.7;References;727
20.5;Chapter 86 C1 Inhibitor Autoantibodies;730
20.5.1;Abstract;730
20.5.2;Historical notes;730
20.5.3;The Autoantigen;731
20.5.4;The autoantibody;732
20.5.5;Clinical utility;733
20.5.6;Take-home messages;735
20.5.7;References;735
20.6;Chapter 87 Autoantibodies to C1q;738
20.6.1;Abstract;738
20.6.2;Historical notes;738
20.6.3;Autoantigen;739
20.6.4;Autoantibody;741
20.6.5;Clinical utility;742
20.6.6;Conclusions;745
20.6.7;Take-home messages;745
20.6.8;References;746
20.7;Chapter 88 Anti-Collagen Antibodies;748
20.7.1;Abstract;748
20.7.2;Historical notes;748
20.7.3;Collagen as an autoantigen;749
20.7.4;Autoantibody;751
20.7.5;Clinical utility;752
20.7.6;Take-home messages;753
20.7.7;References;753
20.8;Chapter 89 Anti-Cyclic Citrullinated Peptide Antibody;756
20.8.1;Historical perspective;756
20.8.2;Antibody/antigen;756
20.8.3;Summary;758
20.8.4;References;758
20.9;Chapter 90 Anti-Endothelial Cell Autoantibodies;760
20.9.1;Abstract;760
20.9.2;Historical notes;761
20.9.3;Autoantigens;761
20.9.4;Autoantibodies;763
20.9.5;Clinical utility;765
20.9.6;Take-home messages;766
20.9.7;References;766
20.10;Chapter 91 Lupus Anticoagulant Testing;768
20.10.1;Abstract;768
20.10.2;Historical notes;769
20.10.3;Autoantigen;769
20.10.4;Autoantibody;770
20.10.5;Clinical utility;771
20.10.6;Take-home messages;773
20.10.7;References;773
20.11;Chapter 92 Anticardiolipin Antibodies;776
20.11.1;Abstract;776
20.11.2;Historical notes;776
20.11.3;Autoantigens;777
20.11.4;Autoantibodies;777
20.11.5;Clinical utility;779
20.11.6;Take-home messages;780
20.11.7;References;780
20.12;Chapter 93 Phospholipid Autoantibodies (Non-Anticardiolipin)–Anti-Prothrombin Antibodies;782
20.12.1;Abstract;782
20.12.2;Historical notes;782
20.12.3;Detection methods and immunological properties;783
20.12.4;Epitope mapping;784
20.12.5;Mechanisms of action;784
20.12.6;Pathophysiology of thrombosis and miscarriage;785
20.12.7;Clinical relevance;785
20.12.8;Treatment;786
20.12.9;Take-home messages;787
20.12.10;References;787
20.13;Chapter 94 Rheumatoid Factors;790
20.13.1;Abstract;790
20.13.2;Historical notes;790
20.13.3;Autoantigen;791
20.13.4;Autoantibodies;792
20.13.5;Clinical utility;795
20.13.6;Take-home messages;797
20.13.7;References;797
21;Part XIII Skin Disease Autoantibodies;798
21.1;Chapter 95 Autoantibodies to Mucocutaneous Antigens;800
21.1.1;Abstract;800
21.1.2;Historical notes;801
21.1.3;Type II Mucocutaneous autoimmunity: Epidermal antigens;803
21.1.4;Type II Mucocutaneous autoimmunity: Dermal antigens;809
21.1.5;Conclusion;812
21.1.6;Take-home messages;812
21.1.7;Acknowledgment;813
21.1.8;References;813
22;Part XIV Unique Clinical Situations;816
22.1;Chapter 96 Autoimmunity and the Newer Biopharmaceuticals;818
22.1.1;Abstract;818
22.1.2;Introduction;819
22.1.3;Toxicity profile and autoimmunity;820
22.1.4;Antinuclear, anti-dsDNA and anti-phospholipid antibodies;821
22.1.5;Possible mechanisms involved in the production of neutralising and non-neutralising autoantibodies during anti-TNF-alpha treatment;823
22.1.6;Conclusions;825
22.1.7;References;825
22.2;Chapter 97 Autoantibodies Against Tumor Suppressor Proteins;828
22.2.1;Abstract;828
22.2.2;Historical notes;829
22.2.3;Retinoblastoma (RB) gene;829
22.2.4;p16 gene;830
22.2.5;p73 gene;831
22.2.6;Conclusion;832
22.2.7;References;833
22.3;Chapter 98 Detection of Autoantibodies Using Protein Arrays;834
22.3.1;Abstract;834
22.3.2;Introduction;834
22.3.3;Early history;835
22.3.4;Preparation and optimal utilization of protein arrays;836
22.3.5;Application of protein arrays to autoimmunity;837
22.3.6;Protein arrays and proteomics;839
22.3.7;Conclusion;840
22.3.8;References;840
22.4;Chapter 99 Autoantibodies and Pregnancy Loss;844
22.4.1;Abstract;844
22.4.2;Historical notes;844
22.4.3;Autoantigens;845
22.4.4;Autoantibodies;845
22.4.5;Clinical utility;847
22.4.6;References;848
23;Part XV Future Directions;850
23.1;Chapter 100 Anti-Glycan Antibodies;852
23.1.1;Abstract;852
23.1.2;Glycan antigens;853
23.1.3;Anti-glycan antibodies in normal population;853
23.1.4;Anti-glycan antibodies in multiple sclerosis;854
23.1.5;Anti-glycan antibodies in inflammatory bowel disease;855
23.1.6;Take-home messages;856
23.1.7;References;857
23.2;Chapter 101 Future Trends;858
23.2.1;Abstract;858
23.2.2;The past;858
23.2.3;The Present;859
23.2.4;The Future;859
23.2.5;Take-home messages;860
23.2.6;References;860
24;Index;862
25;Color Plates;874
